| CAP | camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab... |
|---|---|
| CMAP | compound muscle (or motor) action potential |
| CNAP | career nurse assistants' programs; compound nerve action potential |
| COMAC/HRS/QA | Community Concerted Action Programme on Quality Assurance in Health Care [European] |
| DAH | disordered action of the heart |
| drug interaction | <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other. (18 Jul 2002) |
|---|---|
| drug labelling | Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information. (12 Dec 1998) |
| drug monitoring | The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. (12 Dec 1998) |
| drug, over-the-counter | Drug for which a prescription is not needed. (12 Dec 1998) |
| drug packaging | Containers, packaging, and packaging materials for drugs and biological products. These include those in ampule, capsule, tablet, solution or other forms. Packaging includes immediate-containers, secondary-containers, and cartons. In the united states, such packaging is controlled under the federal food, drug, and cosmetic act which also stipulates requirements for tamper-resistance and child-resistance. Similar laws govern use elsewhere. drug labeling is also available. (12 Dec 1998) |
| drug pathogenesis | The production of morbid symptoms by drugs. (05 Mar 2000) |
| drug, prescription | A drug requiring a prescription, a physician's order. By comparison with an over-the-counter drug. (12 Dec 1998) |
| drug psychosis | Psychosis following or precipitated by ingestion of a drug, e.g., LSD. (05 Mar 2000) |
| drug rash | Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. (12 Dec 1998) |
| drug residues | Drugs and their metabolites which are found in the edible tissues and milk of animals after their medication with specific drugs. This term can also apply to drugs found in adipose tissue of humans after drug treatment. (12 Dec 1998) |
| drug resistance | The ability of bacteria and other microorganisms to withstand a drug to which they were once sensitive (and were once stalled or killed outright). (12 Dec 1998) |
| drug resistance, microbial | The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through plasmids containing resistance factors (r factors). (12 Dec 1998) |
| drug resistance, multiple | Simultaneous resistance to a broad spectrum of structurally and functionally distinct drugs following exposure to a single agent. It is thought to result from the overexpression of genes encoding an integral plasma membrane protein, p-glycoprotein. (12 Dec 1998) |
| drug resistance, neoplasm | Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. (12 Dec 1998) |
| drug resistant | Unresponsive to the desired effects of drugs or other therapy for example: irradiation cytotoxic agents or hormones. Drug resistance of cells within tumours is probably the major cause of treatment failure. (16 Dec 1997) |